Table: q1_q4_2019_prescription_drugs_wac_increases , manufacturer_name like V*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id manufacturer_name date_reported ndc_number drug_product_description wac_effective_date wac_increase_amount wac_after_increase patent_expiration_date drug_source_type unit_sales_volume_in_us unit_sales_volume_non_public_indicator cost_increase_factors cost_increase_factors_non_public_indicator change_improvement_description change_improvement_non_public_indicator acquisition_date company_acquired_from acquisition_price acquisition_price_non_public_indicator acquisition_price_comment wac_at_acquisition wac_year_prior_to_acquisition year_drug_introduced_to_market wac_at_intro_to_market supporting_documents general_comments
Rx0000097 Valeant Pharmaceuticals North America, LLC 03/31/2019 00187006410 ATIVAN® Tablets 1mg 1,000s 01/18/2019 1830.35 32336.16 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The NDC# for this product changed on 02/03/2014. The product was not acquired within the last 5 years
Rx0000097 Valeant Pharmaceuticals North America, LLC 03/31/2019 00187006301 ATIVAN® Tablets .5mg 100s 01/18/2019 139.90 2471.60 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The NDC# for this product changed on 02/03/2014. The product was not acquired within the last 5 years
Rx0000097 Valeant Pharmaceuticals North America, LLC 03/31/2019 00187006401 ATIVAN® Tablets 1mg 100s 01/18/2019 186.89 3301.70 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The product was not acquired within the last 5 years.
Rx0000097 Valeant Pharmaceuticals North America, LLC 03/31/2019 00187006501 ATIVAN® Tablets 2mg 100s 01/18/2019 297.84 5261.87 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The NDC# for this product changed on 12/12/2013. The product was not acquired within the last 5 years.
Rx0000097 Valeant Pharmaceuticals North America, LLC 03/31/2019 00187510001 ELIDEL® (pimecrolimus) Cream 1% 01/18/2019 16.93 299.05 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The product was not acquired within the last 5 years.
Rx0000097 Valeant Pharmaceuticals North America, LLC 03/31/2019 00187510102 ELIDEL® (pimecrolimus) Cream 1% 01/18/2019 33.86 598.11 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The product was not acquired within the last 5 years.
Rx0000097 Valeant Pharmaceuticals North America, LLC 03/31/2019 00187510203 ELIDEL® (pimecrolimus) Cream 1% 01/18/2019 56.42 996.83 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The product was not acquired within the last 5 years.
Rx0000097 Valeant Pharmaceuticals North America, LLC 03/31/2019 00187305050 ONEXTON™ (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/3.75% 01/18/2019 31.65 559.16 08/05/2029 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The product was not acquired within the last 5 years.
Rx0000097 Valeant Pharmaceuticals North America, LLC 03/31/2019 00187149825 TIMOPTIC® in OCUDOSE® (TIMOLOL MALEATE OPHTHALMIC SOLUTION) 0.25%, 0.3mL 01/18/2019 23.68 418.27 None Single Source Drug None 1 None 1 None 1 11/06/2015 Aton Pharma, Inc. None 1 None 332.12 None 2009 87.08 None 1.The product was introduced to the market before acquisition by Valeant Pharmaceuticals North America LLC. (VPNA). The year of introduction and WAC at introduction contained in this report is the only information available to VPNA. VPNA has no knowledge of the actual date of introduction nor the WAC at introduction. 2. In regards to the 5 yr. WAN history the product was acquired on 11/06/2015. The information related to WAC history before that day is from publicly available sources and VPNA is unable to verify the accuracy of that information. 3. The NDC# for this product changed on 11/06/2015
Rx0000097 Valeant Pharmaceuticals North America, LLC 03/31/2019 00187149605 TIMOPTIC® in OCUDOSE® (TIMOLOL MALEATE OPHTHALMIC SOLUTION) 0.50%, 0.3mL 01/18/2019 27.00 476.97 None Single Source Drug None 1 None 1 None 1 08/09/2015 Aton Pharma, Inc. None 1 None 378.73 None 2009 104.84 None 1.The product was introduced to the market before acquisition by Valeant Pharmaceuticals North America LLC. (VPNA). The year of introduction and WAC at introduction contained in this report is the only information available to VPNA. VPNA has no knowledge of the actual date of introduction nor the WAC at introduction. 2. In regards to the 5 yr. WAN history the product was acquired on 08/09/2015. The information related to WAC history before that day is from publicly available sources and VPNA is unable to verify the accuracy of that information.
Rx0000097 Valeant Pharmaceuticals North America, LLC 03/31/2019 00187099445 ZOVIRAX® Cream 5gm 01/18/2019 47.79 844.29 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The product was not acquired within the last 5 years.
Rx0000097 Valeant Pharmaceuticals North America, LLC 03/31/2019 00187099395 ZOVIRAX® Ointment 30gm 01/18/2019 82.81 1463.00 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The product was not acquired within the last 5 years.
Rx0000210 Validus Pharmaceuticals 03/31/2019 30698041912 Equetro® (extended release carbamazepine capsules - bottle of 120) 100mg 01/02/2019 40.21 463.46 05/19/2024 Single Source Drug 3482 None API cost increase, Shipping cost increase, Manufacturer cost increases None N/A None None None None None None None None None None None None
Rx0000210 Validus Pharmaceuticals 03/31/2019 30698042312 Equetro® (extended release carbamazepine capsules - bottle of 120)300mg 01/02/2019 50.92 586.87 05/19/2024 Single Source Drug 6660 None API cost increase, Shipping cost increase, Manufacturer cost increases None N/A None None None None None None None None None None None None
Rx0000210 Validus Pharmaceuticals 03/31/2019 30698042112 Equetro®(extended release carbamazepine capsules - bottle of 120) 200mg 01/02/2019 45.33 522.53 05/19/2024 Single Source Drug 13051 None API cost increase, Shipping cost increase, Manufacturer cost increases None N/A None None None None None None None None None None None None
Rx0000210 Validus Pharmaceuticals 06/30/2019 30698006701 Lasix 20mg Tablet 100 count (Bottle of 100) 04/01/2019 6.79 78.29 None Non-innovator Multiple Source Drug 13327 None API cost increase, Shipping cost increase, Manufacturer cost increases None N/A None 12/10/2015 Sanofi 25000000 None purchased as a part of a portfolio from Sanofi, so the 25M acquisition price included a variety of products. 59.63 59.63 2016 59.63 None None
Rx0000210 Validus Pharmaceuticals 06/30/2019 30698006605 Lasix 80mg Tablet 50 count (Bottle of 50) 04/01/2019 7.70 88.70 None Non-innovator Multiple Source Drug 4684 None API cost increase, Shipping cost increase, Manufacturer cost increases None N/A None 12/10/2015 Sanofi 25000000 None purchased as a part of a portfolio from Sanofi, so the 25M acquisition price included a variety of products. 67.57 67.57 2016 67.57 None None
Rx0000210 Validus Pharmaceuticals 06/30/2019 30698006001 Lasix40mg Tablet 100 count (Bottle of 100) 04/01/2019 9.52 109.72 None Non-innovator Multiple Source Drug 21301 None API cost increase, Shipping cost increase, Manufacturer cost increases None N/A None 12/10/2015 Sanofi 25000000 None purchased as a part of a portfolio from Sanofi, so the 25M acquisition price included a variety of products. 83.56 83.56 2016 83.56 None None
Rx0000210 Validus Pharmaceuticals 06/30/2019 30698045801 Lopressor 50mg tablets (Bottle of 100) 04/01/2019 21.87 252.07 None Non-innovator Multiple Source Drug 5209 None API cost increase, Shipping cost increase, Manufacturer cost increases None N/A None None None None None None None None None None None Column 14 - 22 have been left blank as this product was acquired more than 5 years ago.
Rx0000210 Validus Pharmaceuticals 06/30/2019 30698045901 Lopressor100mg tablets (Bottle of 100) 04/01/2019 32.69 376.79 None Non-innovator Multiple Source Drug 824 None API cost increase, Shipping cost increase, Manufacturer cost increases None N/A None None None None None None None None None None None Column 14 - 22 have been left blank as this product was acquired more than 5 years ago.
Rx0000210 Validus Pharmaceuticals 06/30/2019 30698045201 Lotensin HCT 10/12.5 Tablet (Bottle of 100) 04/01/2019 23.12 266.52 None Non-innovator Multiple Source Drug 83 None API cost increase, Shipping cost increase, Manufacturer cost increases None N/A None None None None None None None None None None None Column 14 - 22 have been left blank as this product was acquired more than 5 years ago.
Rx0000210 Validus Pharmaceuticals 06/30/2019 30698045301 Lotensin HCT 20/12.5 Tablet (Bottle of 100) 04/01/2019 23.12 266.52 None Non-innovator Multiple Source Drug 335 None API cost increase, Shipping cost increase, Manufacturer cost increases None N/A None None None None None None None None None None None Column 14 - 22 have been left blank as this product was acquired more than 5 years ago.
Rx0000210 Validus Pharmaceuticals 06/30/2019 30698045401 Lotensin HCT 20/25 Tablet (Bottle of 100) 04/01/2019 23.12 266.52 None Non-innovator Multiple Source Drug 1168 None API cost increase, Shipping cost increase, Manufacturer cost increases None N/A None None None None None None None None None None None Column 14 - 22 have been left blank as this product was acquired more than 5 years ago.
Rx0000098 Vanda Pharmaceuticals Inc. 03/31/2019 43068010102 Fanapt 1 mg tablets; bottles of 60 01/01/2019 87.19 1177.10 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 03/31/2019 43068011002 Fanapt 10 mg tablets; bottles of 60 01/01/2019 171.81 2319.45 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 03/31/2019 43068011202 Fanapt 12 mg tablets; bottles of 60 01/01/2019 171.81 2319.45 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 03/31/2019 43068010202 Fanapt 2 mg tablets; bottles of 60 01/01/2019 87.19 1177.10 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 03/31/2019 43068010402 Fanapt 4 mg tablets; bottles of 60 01/01/2019 87.19 1177.10 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 03/31/2019 43068010602 Fanapt 6 mg tablets; bottles of 60 01/01/2019 107.28 1448.34 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 03/31/2019 43068010802 Fanapt 8 mg tablets; bottles of 60 01/01/2019 107.28 1448.34 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 03/31/2019 43068011304 Fanapt 8 tablet titration pack 01/01/2019 11.62 156.95 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 03/31/2019 43068022001 Hetlioz; 20 mg capsules; bottles of 30 01/01/2019 1163.06 15701.35 02/12/2035 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000066 ViiV Healthcare 03/31/2019 49702022318 SELZENTRY TAB 150MG 01/01/2019 45.33 1556.20 11/25/2022 Single Source Drug None 1 None 1 The price increase listed are not related to any identified or claimed change or improvement. None None None None None None None None None None None Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided.  The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000066 ViiV Healthcare 03/31/2019 49702022418 SELZENTRY TAB 300MG 01/01/2019 45.33 1556.20 11/25/2022 Single Source Drug None 1 None 1 The price increase listed are not related to any identified or claimed change or improvement. None None None None None None None None None None None Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided.  The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000066 ViiV Healthcare 03/31/2019 49702022613 TIVICAY TAB 10MG 01/01/2019 16.58 348.10 12/08/2029 Single Source Drug None 1 None 1 The price increase listed are not related to any identified or claimed change or improvement. None None None None None None None None None None None Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided.  The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000066 ViiV Healthcare 03/31/2019 49702022713 TIVICAY TAB 25MG 01/01/2019 41.44 870.25 12/08/2029 Single Source Drug None 1 None 1 The price increase listed are not related to any identified or claimed change or improvement. None None None None None None None None None None None Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided.  The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000066 ViiV Healthcare 03/31/2019 49702022813 TIVICAY TAB 50MG 01/01/2019 82.88 1740.49 12/08/2029 Single Source Drug None 1 None 1 The price increase listed are not related to any identified or claimed change or improvement. None None None None None None None None None None None Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided.  The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000066 ViiV Healthcare 03/31/2019 49702023113 TRIUMEQ TAB 01/01/2019 84.16 2889.36 12/08/2029 Single Source Drug None 1 None 1 The price increase listed are not related to any identified or claimed change or improvement. None None None None None None None None None None None Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided.  The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.